Alector Reports Second Quarter 2023 Financial Results and Provides Business Update

Closed screening in the INVOKE-2 Phase 2 trial of AL002 in participants with early Alzheimer’s disease; completing enrollment in Q3 2023, with data readout expected in Q4 2024

Presented update on INVOKE-2 at the Alzheimer’s Association International Conference (AAIC)

Anticipate completing enrollment in pivotal INFRONT-3 trial of latozinemab with symptomatic FTD-GRN participants in Q4 2023 based on recent interactions with the FDA and EMA

$630.0 million in cash, cash equivalents and investments provide runway through 2025;
 revenue and expense guidance updated for 2023

Management to host conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT

Alector’s management team will host a conference call discussing Alector’s results for the second quarter of 2023 and provide a business update. The conference call will be webcast and accessible via the investor relations section of Alector’s website at www.alector.com.

To access the call, please use the following information:

Date: Thursday, August 3, 2023
Time: 4:30 p.m. ET, 1:30 p.m. PT

The event will be webcast live under the investor relations section of Alector’s website at https://investors.alector.com/events-and-presentations/events and following the event a replay will be archived there for 30 days. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.

https://finance.yahoo.com/news/alector-reports-second-quarter-2023-200500907.html